


**MORRIS, MANNING & MARTIN, LLP**  
 ATTORNEYS AT LAW

 RECEIVED  
 CENTRAL FAX CENTER  
 NOV 23 2005

**FACSIMILE  
TRANSMISSION  
FORM**
*1600 Atlanta Financial Center  
3343 Peachtree Road, N.E.  
Atlanta, Georgia 30326*
**Facsimile Number: 404-365-9532**

*This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via U.S. Postal Service. Thank you.*

<b>TO:</b>	United States Patent & Trademark Office
<b>DATE &amp; TIME:</b>	November 23, 2005
<b>TOTAL PAGES:</b>	Fifteen (15)
<b>FAX NUMBER:</b>	571-273-8300

<b>FROM:</b> Morris, Manning & Martin, LLP	<b>CHARGE TO:</b> 14507-47022
<b>NAME:</b> Tim Tingkang Xia, Esq.	<b>CLIENT/MATTER:</b>
<b>PHONE:</b> (404) 233-7000	<b>CONFIRMATION TIME:</b>
____ : ____ : ____ HR MIN SEC	

**COMMENTS:**

**RE:** Serial No.: 10/699,393  
**Filing Date:** October 31, 2003  
**Attachments:** Transmittal  
 Response to Restriction Requirement

***IF YOU HAVE ANY DIFFICULTY WITH THIS TRANSMISSION, PLEASE CALL (404) 233-7000***

RECEIVED  
CENTRAL FAX CENTER

S/N 10/699,393

NOV 23 2005

PATENT  
Confirmation No. 3913IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gruber, Andras et al.

Examiner: Swope, Sheridan

Serial No.: 10/699,393

Invention Art Unit: 1656


Filed: October 31, 2003

Docket No.: 14507-47022  
(Formerly E056 1071.1)

Title: Anti-Thrombotic Thrombin Variants

CERTIFICATE UNDER 37 CFR 1.8(a):

I hereby certify that this correspondence is being transmitted by facsimile to number 571-273-8300 addressed to Mail Stop: Non-Fee Amendment, Commissioner for Patents, United States Patent and Trademark Office on November 23, 2005.

By:   
Name: Tim Tingkang XiaTRANSMITTAL

Mail Stop: Non-Fee Amendment  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

November 23, 2005

CUSTOMER NO. 24728

Sir:

We are transmitting herewith the attached:

- Transmittal Sheet containing Certificate of Facsimile Transmission
- Response to Restriction Requirement (13 pages)

MORRIS, MANNING & MARTIN, LLP  
1600 Atlanta Financial Center  
3343 Peachtree Road NE  
Atlanta, Georgia 30326  
404.495.3678  
Customer No. 24728

By:   
Name: Tim Tingkang Xia  
Attorney for the Applicants on the Record  
Reg. No.: 45,242  
TX

S/N 10/699,393


NOV 23 2005

PATENT  
Confirmation No. 3913IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gruber, Andras et al.	Examiner:	Swope, Sheridan
Serial No.:	10/699,393	Invention Art Unit:	1656
Filed:	October 31, 2003	Docket No.:	14507-47022 (Formerly E056 1071.1)
Title:	Anti-Thrombotic Thrombin Variants		

CERTIFICATE UNDER 37 CFR 1.8(a):

I hereby certify that this correspondence is being transmitted by facsimile to number 571-273-8300 addressed to Mail Stop: Non-Fee Amendment, Commissioner for Patents, United States Patent and Trademark Office on November 23, 2005.

By:   
Name: Tim Tingkang Xia

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop: Non-Fee Amendment  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

November 23, 2005

CUSTOMER NO. 24728

Dear Sir:

This paper is being submitted in response to the Restriction Requirement contained in the Office communication mailed October 24, 2005. Without acquiescing to the statements made therein, Applicants hereby elect with traverse the claims of Invention I, claims 1-8, 13-18, 42-45 and 49, for prosecution in the instant application. Applicants further respectfully request at least the claims of Invention III, claims 19-41, which are method claims corresponding to the protein claims of Invention I, be examined together for reasons set forth below. Applicants also amend the above-identified application.

Prior to examining the instant application on its merits, please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.